Cargando…

Clinical and Genomic Factors Associated with Greater Tumor Mutational Burden in Prostate Cancer

Tumor mutational burden (TMB) is a biomarker that predicts response to immune checkpoint inhibitor therapy. We currently lack a comprehensive understanding of how genomic and clinical factors correlate with TMB. We used a clinicogenomic database to assess independent predictors of TMB levels. The st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hougen, Helen Y., Graf, Ryon P., Li, Gerald, Quintanilha, Julia C.F., Lin, Douglas I., Ross, Jeffrey S., Punnen, Sanoj, Mahal, Brandon A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Brief Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470357/ https://www.ncbi.nlm.nih.gov/pubmed/37662703 http://dx.doi.org/10.1016/j.euros.2023.08.001

Ejemplares similares

BRAF V600E and RNF43 Co-mutations Predict Patient Outcomes with Targeted Therapies in Real-World Cases of Colorectal Cancer
por: Quintanilha, Julia C F, et al.
Publicado: (2023)

Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness
por: Quintanilha, Julia C.F., et al.
Publicado: (2023)

Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer
por: Hill, Breana L, et al.
Publicado: (2023)

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden
por: Quintanilha, Julia C. F., et al.
Publicado: (2023)

Real-World Comprehensive Genomic Profiling Success Rates in Tissue and Liquid Prostate Carcinoma Specimens
por: Hiemenz, Matthew C, et al.
Publicado: (2022)

Divorcing Diagnosis From Treatment: Contemporary Management of Low-Risk Prostate Cancer
por: Glass, Allison S., et al.
Publicado: (2013)

Impact of Meat Consumption, Preparation, and Mutagens on Aggressive Prostate Cancer
por: Punnen, Sanoj, et al.
Publicado: (2011)

Imaging for the selection and monitoring of men on active surveillance for prostate cancer
por: Velasquez, Maria C., et al.
Publicado: (2018)

TERT Promoter Mutations in Keratinizing and Nonkeratinizing Squamous Metaplasia of the Urinary Tract
por: Taylor, Alexander S., et al.
Publicado: (2022)

The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer
por: Shaw, Greg L., et al.
Publicado: (2016)

Prostate Cancer Risk by BRCA2 Genomic Regions
por: Nyberg, Tommy, et al.
Publicado: (2020)

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer
por: Graf, Ryon P., et al.
Publicado: (2022)

Hypofractionation of radiation dose to the prostate does not necessarily imply a greater risk of acute radiation proctitis
por: Ferini, Gianluca, et al.
Publicado: (2023)

Addition of Prostate Volume and Prostate-specific Antigen Density to Memorial Sloan Kettering Cancer Center Prostate Cancer Nomograms
por: Tzeng, Michael, et al.
Publicado: (2021)

Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [(177)Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer
por: Stangl-Kremser, Judith, et al.
Publicado: (2021)

The right to be screened: Identifying and addressing inequities in genetic screening
por: Swami, Nishwant, et al.
Publicado: (2022)

Nationally-representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America Project
por: Cary, K. Clint, et al.
Publicado: (2015)

Implementation of 4Kscore as a Secondary Test Before Prostate Biopsy: Impact on US Population Trends for Prostate Cancer
por: Scuderi, Simone, et al.
Publicado: (2023)

A greater focus on prevention and rehabilitation
por: Zhu, Ziqing
Publicado: (2012)

What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021
por: Turco, Fabio, et al.
Publicado: (2022)

Addition of a Genetic Risk Score for Identification of Men with a Low Prostate-specific Antigen Level in Midlife at Risk of Developing Lethal Prostate Cancer
por: Ma, Chaoran, et al.
Publicado: (2023)

Aggressive Prostate Cancer at Presentation Following Solid Organ Transplantation
por: Singh, Zorawar, et al.
Publicado: (2022)

Entering an era of radiogenomics in prostate cancer risk stratification
por: Soodana-Prakash, Nachiketh, et al.
Publicado: (2018)

Using a Recurrent Neural Network To Inform the Use of Prostate-specific Antigen (PSA) and PSA Density for Dynamic Monitoring of the Risk of Prostate Cancer Progression on Active Surveillance
por: Sushentsev, Nikita, et al.
Publicado: (2023)

Patterns of Care and Treatment Outcomes in Locoregional Squamous Cell Carcinoma of the Prostate
por: Hutten, Ryan J., et al.
Publicado: (2021)

Multiparametric-MRI and Targeted Biopsies in the Management of Prostate Cancer Patients on Active Surveillance
por: Sandler, Kiri, et al.
Publicado: (2015)

Mobile PSA: A Novel Telehealth Tool for Prostate Cancer Follow-Up
por: Bergroth, Robin, et al.
Publicado: (2021)

Micro-ultrasound Versus Magnetic Resonance Imaging in Prostate Cancer Active Surveillance
por: Albers, Patrick, et al.
Publicado: (2022)

A survey on the attitudes towards research in medical school
por: Siemens, D Robert, et al.
Publicado: (2010)

Patient-reported Experience of Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 Countries
por: Giles, Rachel, et al.
Publicado: (2022)

Salvage Radiotherapy Following Partial Gland Ablation for Prostate Cancer: Functional and Oncological Outcomes
por: Qaoud, Yazan, et al.
Publicado: (2020)

Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
por: Fallara, Giuseppe, et al.
Publicado: (2023)

Implications of the European Association of Urology Recommended Risk Assessment Algorithm for Early Prostate Cancer Detection
por: Israël, Bas, et al.
Publicado: (2022)

Leveraging Social Media as a Thermometer to Gauge Patient and Caregiver Concerns: COVID-19 and Prostate Cancer
por: Loeb, Stacy, et al.
Publicado: (2021)

Overexpression of Placental Growth Factor in Stromal Cells from Benign Prostatic Hyperplasia: Another Piece in the Puzzle?
por: Devlin, Conor M., et al.
Publicado: (2020)

In-depth Analysis of the 2019 Advanced Prostate Cancer Consensus Conference: The Importance of Representation of Medical Specialty and Geographic Regions
por: Pratsinis, Manolis, et al.
Publicado: (2021)

Oligometastasis in Prostate Cancer: Can We Learn from Those “Excluded” from a Phase 2 Trial?
por: Glicksman, Rachel M., et al.
Publicado: (2023)

How to follow the new EU Council recommendation and improve prostate cancer early detection: the Prostaforum 2022 declaration
por: Májek, Ondřej, et al.
Publicado: (2023)

External Validation of a Prediction Model for Side-specific Extraprostatic Extension of Prostate Cancer at Robot-assisted Radical Prostatectomy
por: Veerman, Hans, et al.
Publicado: (2022)

Updating the Rotterdam Prostate Cancer Risk Calculator with Invasive Cribriform and/or Intraductal Carcinoma for Men with a Prior Negative Biopsy
por: Remmers, Sebastiaan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9qms10qvckvkonuip54so6a02i